AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16984654 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine
Number of subjects: 16
Study 16984654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14528656 — intervention group
Group type: EXPERIMENTAL
Intervention: H1‐receptor antagonist (0.1 mg/kg BW dimetindene) plus H2‐receptor antagonist (5 mg/kg BW cimetidine) diluted with 100 ml 0.9% NaCl
Number of subjects: 17
Study 14528656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml 0.9% NaCl)
Number of subjects: 17
Study 14528656 — intervention group
Group type: EXPERIMENTAL
Intervention: H1‐receptor antagonist plus H2‐receptor antagonist
Number of subjects: 17
Study 10632409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection
Number of subjects: 76
Study 10632409 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 76
Study 9361539 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional repeated colloid fluid challenges with oesophageal Doppler ultrasonography
Number of subjects: 40
Study 9361539 — intervention group
Group type: COMPARATOR
Intervention: Conventional intraoperative fluid management (control)
Number of subjects: 40
Study 1490088 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol eye drops
Number of subjects: 72
Study 1490088 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol eye drops
Number of subjects: 72
Study 1490088 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 72
Study 3985778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating air mattress
Number of subjects: 32
Study 3985778 — intervention group
Group type: COMPARATOR
Intervention: Silicore mattress
Number of subjects: 32
Study 30920646 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to bear adversity (trading quality of life for survival)
Number of subjects: 524
Study 30920646 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute certainty about curability (ACC)
Number of subjects: 524
Study 30920646 — intervention group
Group type: COMPARATOR
Intervention: Willingness to bear treatment-related toxicities
Number of subjects: 524
Study 29438157 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/d)
Number of subjects: 30
Study 29438157 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/d) + Low-dose Naltrexone (25 mg/d)
Number of subjects: 30
Study 29438157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27070952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 148
Study 27070952 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 148
Study 24615211 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Waiguan TE5 and Qiuxu GB40)
Number of subjects: 20
Study 24615211 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Neiguan PC6 and Taichong LR3)
Number of subjects: 20
Study 24615211 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 22546895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous buspirone (0.3 mg)
Number of subjects: 257
Study 22546895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous buspirone (1.0 mg)
Number of subjects: 257
Study 22546895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 21526663 — intervention group
Group type: COMPARATOR
Intervention: Supine position (group S)
Number of subjects: 120
Study 21526663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position (group L)
Number of subjects: 120
Study 18550874 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg of hemagglutinin antigen without adjuvant
Number of subjects: 275
Study 18550874 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of hemagglutinin antigen without adjuvant
Number of subjects: 275
Study 18550874 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg, 7.5 microg, 15 microg, or 30 microg of hemagglutinin antigen with alum adjuvant
Number of subjects: 275
Study 18550874 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine formulations
Number of subjects: 275
Study 15821819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dalteparin
Number of subjects: 20
Study 12057022 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshops
Number of subjects: 179
Study 12057022 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to completion of Cochrane reviews
Number of subjects: 179
Study 9931171 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of brisk walking 5 to 7 times weekly for 12 weeks
Number of subjects: 20
Study 7752011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU for children <1 year, 200,000 IU for older children)
Number of subjects: 263
Study 7752011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 2175139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 or 4 mg in an iv bolus 10 min before insulin or smoking)
Number of subjects: 24
Study 2175139 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.15 IU/kg in an iv bolus)
Number of subjects: 24
Study 2175139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (2 non-filter cigarettes smoked in succession within 10 min)
Number of subjects: 24
Study 2175139 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (2 or 4 mg in an iv bolus)
Number of subjects: 24
Study 2175139 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycemia
Number of subjects: 24
Study 7017189 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Keflex
Number of subjects: 215
Study 7017189 — intervention group
Group type: COMPARATOR
Intervention: Keflex
Number of subjects: 215
Study 31285062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=20)
Number of subjects: 40
Study 28390794 — intervention group
Group type: EXPERIMENTAL
Intervention: First view on the postbiopsy mammogram obtained in the same projection as that used during the biopsy procedure (group 1)
Number of subjects: 60
Study 28390794 — intervention group
Group type: COMPARATOR
Intervention: First view on the postbiopsy mammogram obtained orthogonally to the projection used during the biopsy procedure (group 2)
Number of subjects: 60
Study 26180356 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band resistance exercise program (3 times per week for five months)
Number of subjects: 23
Study 23477995 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical examination alone
Number of subjects: 15239
Study 23477995 — intervention group
Group type: COMPARATOR
Intervention: Laboratory tests plus standardized physical examination
Number of subjects: 15239
Study 21680993 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch® Delica™
Number of subjects: 200
Study 21680993 — intervention group
Group type: COMPARATOR
Intervention: OneTouch® Comfort™
Number of subjects: 200
Study 21680993 — intervention group
Group type: COMPARATOR
Intervention: ACCU‐CHEK® Softclix
Number of subjects: 200
Study 21680993 — intervention group
Group type: COMPARATOR
Intervention: ACCU‐CHEK® Multiclix
Number of subjects: 200
Study 21680993 — intervention group
Group type: COMPARATOR
Intervention: Ascensia® Microlet™2
Number of subjects: 200
Study 18602635 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) - 25% calorie restriction
Number of subjects: 36
Study 18602635 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with exercise (CR+EX) - 12.5% CR + 12.5% increase in energy expenditure via aerobic exercise
Number of subjects: 36
Study 18602635 — intervention group
Group type: COMPARATOR
Intervention: Control - 100% of energy requirements
Number of subjects: 36
Study 16673799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% shampoo, treated once daily for 4 weeks, rinsed off after 15 minutes
Number of subjects: 26
Study 16673799 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate gel, leave-on formulation
Number of subjects: 26
Study 16673799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo and gel
Number of subjects: 26
Study 12823492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX; Mirapexin)
Number of subjects: 41
Study 12823492 — intervention group
Group type: COMPARATOR
Intervention: Pergolide (PRG; Permax)
Number of subjects: 41
Study 10814600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 10
Study 10814600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8634406 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine-sodium-ioxaglate (Hexabrix)
Number of subjects: 60
Study 8634406 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (Ultravist)
Number of subjects: 60
Study 1643675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative iv clonidine (Group 1)
Number of subjects: 200
Study 1643675 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia alone (Group 2)
Number of subjects: 200
Study 6608858 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate for one year
Number of subjects: 22
Study 6608858 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 22
Study 30484269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) dosed at bedtime
Number of subjects: 175
Study 30484269 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) dosed in the morning
Number of subjects: 175
Study 29796596 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic music improvisation with a music therapist (MT)
Number of subjects: 60
Study 29796596 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded music listening (ML)
Number of subjects: 60
Study 29796596 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study 26802087 — intervention group
Group type: EXPERIMENTAL
Intervention: AVX-470 at 3.5g/day
Number of subjects: 36
Study 26802087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24474305 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of telephone cessation counseling
Number of subjects: 214
Study 24474305 — intervention group
Group type: COMPARATOR
Intervention: U.S. Public Health Service Clinical Practice Guideline information
Number of subjects: 214
Study 22155457 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg)
Number of subjects: 20
Study 22155457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22155457 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg)
Number of subjects: 20
Study 20082585 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin
Number of subjects: 119
Study 20082585 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 119
Study 17640310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (900 mg daily for 21 days, then 900 mg daily for 28 days)
Number of subjects: 321
Study 17640310 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg twice daily for 21 days)
Number of subjects: 321
Study 17640310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 321
Study 15911902 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR strategy
Number of subjects: 2317
Study 15911902 — intervention group
Group type: COMPARATOR
Intervention: Atenolol strategy
Number of subjects: 2317
Study 12409329 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 micro g
Number of subjects: 133
Study 12409329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 10089184 — intervention group
Group type: COMPARATOR
Intervention: D1 lymph-node dissection
Number of subjects: 996
Study 10089184 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymph-node dissection
Number of subjects: 996
Study 7478041 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI-dipy
Number of subjects: 60
Study 7478041 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO-dipy
Number of subjects: 60
Study 1975746 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP1)
Number of subjects: 50
Study 1975746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 114127 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 1332
Study 114127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1332
Study 31987116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet containing 50 g of Kashk (intervention group)
Number of subjects: 70
Study 31987116 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet without Kashk (control group)
Number of subjects: 70
Study 30367257 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide-based intracanal medication (ICM) after 30 days
Number of subjects: 20
Study 30367257 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine (CHX) gel
Number of subjects: 20
Study 30367257 — intervention group
Group type: COMPARATOR
Intervention: 6% sodium hypochlorite (NaOCl)
Number of subjects: 20
Study 28891855 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 600
Study 28891855 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl/midazolam
Number of subjects: 600
Study 26421166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 92
Study 26421166 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 92
Study 26421166 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 92
Study 23405158 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR1 at 24 hours
Number of subjects: 48
Study 23405158 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative increases in sTNFR1 and sTNFR2 over 24 hours
Number of subjects: 48
Study 23405158 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFRs
Number of subjects: 48
Study 23405158 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble Fas and sFasL
Number of subjects: 48
Study 23405158 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptosis markers
Number of subjects: 48
Study 21941411 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 400 mg/day from 12th week gestation until 4 months postpartum
Number of subjects: 60
Study 21941411 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 19678875 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal fantasies focusing on motive-specific affective incentives
Number of subjects: 273
Study 19678875 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical goal selection
Number of subjects: 273
Study 19678875 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment to personal goals
Number of subjects: 273
Study 16858634 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session HIV and trauma coping group intervention
Number of subjects: 202
Study 16858634 — intervention group
Group type: COMPARATOR
Intervention: 15-session support group comparison condition
Number of subjects: 202
Study 16858634 — intervention group
Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 202
Study 15385901 — intervention group
Group type: EXPERIMENTAL
Intervention: WiLLOW intervention
Number of subjects: 366
Study 11133605 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusions
Number of subjects: 100
Study 11133605 — intervention group
Group type: COMPARATOR
Intervention: Meperidine boluses
Number of subjects: 100
Study 9644229 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, n=6; 100 mg, n=2; 120 mg, n=1)
Number of subjects: 9
Study 9644229 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 9
Study 9644229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Five syndrome model based on factor analysis
Number of subjects: 240
Study 7831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and Negative Syndrome Scale (PANSS)
Number of subjects: 240
Study 2757891 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (inhibitor of the sodium/potassium pump)
Number of subjects: 0
Study 2757891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (inhibitor of the anion transporter)
Number of subjects: 0
Study 2757891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (oral load)
Number of subjects: 0
Study 1023958 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium and endotracheal intubation
Number of subjects: 20
Study 1023958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pancuronium)
Number of subjects: 20
Study 31768805 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic relatedness in productive test
Number of subjects: 0
Study 31768805 — intervention group
Group type: COMPARATOR
Intervention: Semantic unrelated items in receptive test
Number of subjects: 0
Study 31768805 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic relatedness in Experiment 2
Number of subjects: 0
Study 31768805 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic relatedness in language input
Number of subjects: 0
Study 30421856 — intervention group
Group type: COMPARATOR
Intervention: IBT (IBT‐alone)
Number of subjects: 150
Study 30421856 — intervention group
Group type: EXPERIMENTAL
Intervention: IBT combined with liraglutide (IBT‐liraglutide)
Number of subjects: 150
Study 30421856 — intervention group
Group type: EXPERIMENTAL
Intervention: IBT‐liraglutide combined with meal replacements (Multicomponent)
Number of subjects: 150
Study 28627349 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal lifting and compression CPR
Number of subjects: 66
Study 28627349 — intervention group
Group type: COMPARATOR
Intervention: Unarmed abdominal compression CPR
Number of subjects: 66
Study 26107215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin 50mg/m2, MMC 16mg/m2, Vincristine 2mg/m2 every 21 days (Group A)
Number of subjects: 86
Study 26107215 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100mg/m2, MMC 16mg/m2, Vincristine 2mg/m2 every 21 days (Group B)
Number of subjects: 86
Study 23499390 — intervention group
Group type: EXPERIMENTAL
Intervention: Enobosarm 1 mg
Number of subjects: 159
Study 23499390 — intervention group
Group type: EXPERIMENTAL
Intervention: Enobosarm 3 mg
Number of subjects: 159
Study 23499390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 21448267 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (n=99 provided data)
Number of subjects: 277
Study 21448267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture (n=101 provided data)
Number of subjects: 277
Study 21448267 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=62 provided data)
Number of subjects: 277
Study 21448267 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture cohort (verum and sham combined)
Number of subjects: 277
Study 19553295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine ingestion (1 mmol lysine/kg lean body mass)
Number of subjects: 13
Study 19553295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine plus glucose (25 g glucose)
Number of subjects: 13
Study 19553295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine ingestion
Number of subjects: 13
Study 19553295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine plus glucose
Number of subjects: 13
Study 19553295 — intervention group
Group type: COMPARATOR
Intervention: Glucose ingestion
Number of subjects: 13
Study 22222469 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 55
Study 22222469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 22222469 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide
Number of subjects: 55
Study 15987985 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma brachytherapy with an iridium 192 source (14-Gy dose at 2 mm into the arterial wall)
Number of subjects: 88
Study 15987985 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation only
Number of subjects: 88
Study 15987985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent and brachytherapy group
Number of subjects: 88
Study 12583947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (n-3 PUFAs)
Number of subjects: 188
Study 12583947 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil capsules (n-6 PUFAs)
Number of subjects: 188
Study 12583947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 188
Study 10808387 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL from segment A (s.A)
Number of subjects: 28
Study 10808387 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL from segment B (s.B)
Number of subjects: 28
Study 10808387 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood
Number of subjects: 28
Study 10808387 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 28
Study 7484831 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal atrial defibrillation using biphasic shocks with the right atrium (RA) and left pulmonary artery or coronary sinus (CS) configuration.
Number of subjects: 18
Study 7484831 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle (RV) and superior vena cava configuration.
Number of subjects: 18
Study 7484831 — intervention group
Group type: COMPARATOR
Intervention: RA and axilla configuration.
Number of subjects: 18
Study 7484831 — intervention group
Group type: EXPERIMENTAL
Intervention: RV to RA configuration.
Number of subjects: 18
Study 7484831 — intervention group
Group type: EXPERIMENTAL
Intervention: RA-left pulmonary artery/CS configuration.
Number of subjects: 18
Study 7484831 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks delivered without anesthesia.
Number of subjects: 18
Study 7484831 — intervention group
Group type: EXPERIMENTAL
Intervention: Shocks > or = 3 J.
Number of subjects: 18
Study 2110954 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.25 mg/kg
Number of subjects: 80